Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or
refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT